News
BCYC
4.200
-3.00%
-0.130
Weekly Report: what happened at BCYC last week (0817-0821)?
Weekly Report · 5d ago
Possible Signal As Bicycle Therapeutics Insiders Sell US$523k In Stock
Simply Wall St · 08/22 12:10
Bicycle Therapeutics Announces Board and Advisory Resignation
TipRanks · 08/20 21:14
Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TipRanks · 08/17 15:30
Weekly Report: what happened at BCYC last week (0810-0814)?
Weekly Report · 08/17 09:10
Weekly Report: what happened at BCYC last week (0803-0807)?
Weekly Report · 08/10 09:10
Bicycle: 'Hold' On Zelenectide Deprioritization And Shift To EphA2+ Tumor Targeting
Seeking Alpha · 08/04 14:40
Weekly Report: what happened at BCYC last week (0727-0731)?
Weekly Report · 08/03 09:10
RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)
TipRanks · 08/01 01:46
Bicycle a new outperform at Oppenheimer on platform to treat cancer
Seeking Alpha · 07/31 15:54
Bicycle Therapeutics assumed with an Outperform at Oppenheimer
TipRanks · 07/31 12:00
Truist Financial Remains a Hold on Bicycle Therapeutics (BCYC)
TipRanks · 07/31 11:45
Bicycle Therapeutics Q2 Loss Narrows; Advances Cancer Pipeline
NASDAQ · 07/31 06:56
Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Stryker (SYK) and Bicycle Therapeutics (BCYC)
TipRanks · 07/31 06:00
Bicycle Therapeutics Price Target Cut to $14.00/Share From $15.00 by Needham
Dow Jones · 07/30 19:26
Bicycle Therapeutics Is Maintained at Buy by Needham
Dow Jones · 07/30 19:26
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14
Benzinga · 07/30 19:15
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)
TipRanks · 07/30 16:40
Bicycle Therapeutics Q2 EPS $(0.72) Misses $(0.59) Estimate, Sales $629.000K Miss $4.221M Estimate
Benzinga · 07/30 11:56
Bicycle Therapeutics sees cash runway into 2030
TipRanks · 07/30 11:11
More
Webull provides a variety of real-time BCYC stock news. You can receive the latest news about Bicycle Therapeutics Limited through multiple platforms. This information may help you make smarter investment decisions.
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.